Last reviewed · How we verify
losartan (drug)
Losartan blocks angiotensin II receptors on blood vessels and tissues, preventing vasoconstriction and reducing blood pressure.
Losartan blocks angiotensin II receptors on blood vessels and tissues, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Diabetic nephropathy in patients with type 2 diabetes.
At a glance
| Generic name | losartan (drug) |
|---|---|
| Sponsor | Odense University Hospital |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the AT1 receptor subtype. By preventing angiotensin II from binding to these receptors, it causes vasodilation, reduces aldosterone secretion, and decreases sodium and water retention, leading to lower blood pressure and reduced cardiac workload.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Diabetic nephropathy in patients with type 2 diabetes
- Post-myocardial infarction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
- Headache
Key clinical trials
- The Effect of Losartan on Cephalexin (PHASE1)
- Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease (PHASE2)
- Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma (PHASE1)
- Losartan for Corneal Fibrosis (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- The COVID-RASi Trial (COVID-19) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- losartan (drug) CI brief — competitive landscape report
- losartan (drug) updates RSS · CI watch RSS
- Odense University Hospital portfolio CI